Urinary Bladder, OveractivePhase 4NCT01054222
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
A Phase 4 study testing Fesoterodine in people with Urinary Bladder, Overactive, run by Pfizer at 3 sites in Portugal.
Trial summary
This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended use of Fesoterodine. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Urinary Bladder, Overactive
- What is being tested?
- Fesoterodine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 31 participants
- Where
- 3 sitesPortugal
- Study dates
- May 2010to Jan 2012
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Subjects must have previously completed fesoterodine study A0221045 [in Portugal]
- Subjects must be recommended for inclusion by the investigator
Who cannot join
- Conditions or states excluding use of fesoterodine e.g. contraindication to fesoterodine
- Predominant stress incontinence as determined by the investigator
Trial locations and contacts
3 sites in 1 country.
Portugal3 sites
Centro de Avaliação Geriátrica
Lisbon, 1990-273
Hospital Ordem do Carmo
Porto, 4099-005
Hospital de São João
Porto, 4200-319
About this study
Official title: A Local, Multicentre, Open-Label, Extension Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder
This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended use of Fesoterodine. Data from this study will extend the evaluation of efficacy, tolerability and safety of Fesoterodine in older subjects from Portugal.
- Conditions
- Urinary Bladder, Overactive
- Being tested
- Fesoterodine
- Keywords
- overactive bladder idiopathic, elderly fesoterodine SOFIA Portugal extension study
- Medical subject headings
- Urinary Bladder, Overactive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FesoterodineDrug
Also called Toviaz
Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
FesoterodineDrug
Also called Toviaz
Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
| Study group | Role | What they receive |
|---|---|---|
| Fesoterodine 4 mg | Other | Dose determined as per previous drug regime in A0221045 and investigator's evaluation. Receives: Drug: Fesoterodine |
| Fesoterodine 8 mg | Other | Dose determined as per previous drug regime in A0221045 and investigator's evaluation. Receives: Drug: Fesoterodine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Number of Micturition-Related Urgency Episodes Per 24 Hours (End of Treatment [EOT])
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with Urinary Sensation Scale (USS) rating of greater than or equal to (>=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: End of Treatment (up to Week 82)
Secondary outcomes (15)
Mean Number of Micturition-Related Urgency Episodes Per 24 Hours
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18
Mean Number of Severe Micturition-Related Urgency Episodes Per 24 Hours
The mean number of severe micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (>=) 4 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Mean Number of Micturitions Per 24 Hours
Micturitions include episodes of voluntary micturition and episodes of Urgency Urinary Incontinence (UUI). UUI episodes were defined as those micturitions with USS rating of 5 in the diary in participants with UUI at baseline. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Mean Number of Nocturnal Micturitions Per 24 Hours
Nocturnal micturitions were defined as micturitions with USS rating 1-5 that occurred between the time the participant went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The mean number of nocturnal micturitions per 24 hours was calculated as the total number of nocturnal micturitions divided by the total number of diary days collected at that visit.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours
UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Daily Sum Rating on the Urinary Sensation Scale (USS)
The daily sum rating was calculated as the mean rating score on the USS multiplied by the mean number of micturitions per 24 hours at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. Numerical decrease indicates improvement.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Percentage of Incontinent Participants at Baseline
UUI episodes were defined as those with the urinary sensation scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline
Percentage of Participants With No Urgency Urinary Incontinence (UUI) Episode
UUI episodes were defined as those with the urinary sensation scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Mean Number of Urinary Incontinence Pads, Barrier Creams and Powder Used Per 24 Hours
The mean number of urinary incontinence pads (IP), barrier creams (BC) and powder used per 24 hours is calculated as the total number of IP, BC and powder used divided by the total number of diary days collected at that visit.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Month 3,6,9,12,15,18, and End of Treatment
PPBC: self-administered, single-item, questionnaire that asked participants to describe their perception of their bladder-related problems. PPBC assessment rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Change = observation minus baseline. Results categorized as Deterioration (score difference ≥1), No Change (score difference=0), Improvement (score difference less than [<]0).
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Number of Participants With Change From Baseline in Patient Perception of Urgency Scale (PPUS) at Months 3,6,9,12,15,18, and End of Treatment
PPUS: self-administered, single-item, questionnaire that measured the participant's perception of urinary urgency. It was sensitive to changes in perceptions of urinary urgency over time. Score of 0 (usually not able to hold urine), 1 (usually able to hold urine [without leaking] until reaching toilet if go to toilet immediately), or 2 (usually able to finish what he/she was doing before going to toilet [without leaking]). Change = observation minus baseline. Deterioration: negative difference of scores; improvement: increase of 1 or more points in difference of scores, relative to baseline.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q)
OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Number of Participants With Response to Overactive Bladder Satisfaction Questionnaire (OAB-s) (Questions 5, 9, 10a-10d, and 11a-11b)
OAB-s assessed OAB medication expectations, daily life with OAB, and satisfaction with OAB medication. Question (Q) 5 evaluates OAB medication expectations (exceeds/meets or does not meet expectation). Q9 to 11 assessed satisfaction with OAB medication's ability to allow reaching bathroom without urine loss (Q9), decrease: sudden urgencies to urinate (Q10a), urine loss due to urgency (Q10b), waking up at night to urinate (Q10c) and urination during day (Q10d), and improve control of urine loss (Q11a) and need to urinate (Q11b). Q9 to 11 were answered as 'very satisfied', 'somewhat satisfied', 'neither dissatisfied nor satisfied', 'somewhat dissatisfied', and 'very dissatisfied'. The results for Q9 to 11 are reported as "satisfied" (participants who answered 'very satisfied' or 'somewhat satisfied' for all 7 questions) or "not satisfied" (participants who answered 'neither dissatisfied nor satisfied' or 'somewhat dissatisfied' or 'very dissatisfied' for all 7 questions).
Measured: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (EOT) (Week 82)
King's Health Questionnaire (KHQ) Domain Scores
KHQ: self-administered questionnaire contained 21 questions scored in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy, and severity of urinary symptoms). Each domain score ranged: 0-100, where 0=best outcome/response and 100=worst outcome/response.
Measured: Baseline, End of Treatment (EOT) (Week 82)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2010 (estimated)
- Study startMay 2010
- Primary completionJan 2012
- Study completionJan 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Urinary Bladder, OveractiveStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01054222
- Sponsor's protocol ID
- A0221090
- Status last verified
- Feb 2013
- First submitted
- 20 Jan 2010
- Last updated
- 15 May 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Local, Multicentre, Open-Label, Extension Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder
- ClinicalTrials.gov ID
- NCT01054222
- Acronym / sponsor ID
- A0221090
- Conditions
- Urinary Bladder, Overactive
- Keywords
- overactive bladder idiopathic, elderly fesoterodine SOFIA Portugal extension study
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- May 2010
- Primary completion
- Jan 2012 (actual)
- Study completion
- Jan 2012 (actual)
- First posted
- 22 Jan 2010 (estimated)
- Results
- Posted 15 May 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended use of Fesoterodine. Data from this study will extend the evaluation of efficacy, tolerability and safety of Fesoterodine in older subjects from Portugal.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fesoterodine 4 mg | Other | Drug: FesoterodineDose determined as per previous drug regime in A0221045 and investigator's evaluation. |
| Fesoterodine 8 mg | Other | Drug: FesoterodineDose determined as per previous drug regime in A0221045 and investigator's evaluation. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (2 listed)
- Subjects must have previously completed fesoterodine study A0221045 [in Portugal]
- Subjects must be recommended for inclusion by the investigator
Key exclusion criteria (2 listed)
- Conditions or states excluding use of fesoterodine e.g. contraindication to fesoterodine
- Predominant stress incontinence as determined by the investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FesoterodineAlso: ToviazFesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier) | Drug | Fesoterodine 4 mg |
| FesoterodineAlso: ToviazFesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier) | Drug | Fesoterodine 8 mg |
Primary outcome
Mean Number of Micturition-Related Urgency Episodes Per 24 Hours (End of Treatment [EOT])
Time frame: End of Treatment (up to Week 82)
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with Urinary Sensation Scale (USS) rating of greater than or equal to (>=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
15 secondary outcomes
Mean Number of Micturition-Related Urgency Episodes Per 24 Hours
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18
Mean Number of Severe Micturition-Related Urgency Episodes Per 24 Hours
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Mean Number of Micturitions Per 24 Hours
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Mean Number of Nocturnal Micturitions Per 24 Hours
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Daily Sum Rating on the Urinary Sensation Scale (USS)
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Percentage of Incontinent Participants at Baseline
Time frame: Baseline
Percentage of Participants With No Urgency Urinary Incontinence (UUI) Episode
Time frame: Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Mean Number of Urinary Incontinence Pads, Barrier Creams and Powder Used Per 24 Hours
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Month 3,6,9,12,15,18, and End of Treatment
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Number of Participants With Change From Baseline in Patient Perception of Urgency Scale (PPUS) at Months 3,6,9,12,15,18, and End of Treatment
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q)
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (Week 82)
Number of Participants With Response to Overactive Bladder Satisfaction Questionnaire (OAB-s) (Questions 5, 9, 10a-10d, and 11a-11b)
Time frame: Baseline, Month 3, 6, 9, 12, 15, 18, End of Treatment (EOT) (Week 82)
King's Health Questionnaire (KHQ) Domain Scores
Time frame: Baseline, End of Treatment (EOT) (Week 82)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Urinary Bladder, Overactive
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
Active, not recruitingObservational study
Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
RecruitingObservational study
Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder
Overactive Bladder (OAB)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Fesoterodine in people with Urinary Bladder, Overactive, run by Pfizer at 3 sites in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 May 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Number of Micturition-Related Urgency Episodes Per 24 Hours (End of Treatment [EOT]) (time frame: End of Treatment (up to Week 82)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2013.